Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ergothioneine is a naturally occurring amino acid and a thiourea derivative of histidine, containing a sulfur atom on the imidazole ring. It is produced by certain bacteria and fungi but not by humans or animals; instead, it is acquired exclusively through the diet, with mushrooms being the richest source. In humans, ergothioneine accumulates in various tissues including erythrocytes (red blood cells), bone marrow, liver, kidney, seminal fluid, and eyes[3]. It acts as an antioxidant and cytoprotective agent in vitro and may be concentrated at sites of tissue injury[4]. Its precise physiological role in humans remains under investigation. Ergothioneine has been studied for potential benefits in conditions such as liver damage, cataracts, Alzheimer's disease, diabetes, heart disease[2], and for skin aging when applied topically. It is sold as a dietary supplement but does not have established pharmaceutical indications or approved medical uses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ergothioneine.